Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]
In development
Reference number: GID-HST10062
Expected publication date: TBC
Biogen has confirmed that it will submit tofersen for the treatment of SOD-1 ALS to the Highly Specialised Technology (HST) Programme in line with NICE’s timelines. As part of our usual process, an invitation to stakeholders to participate in the appraisal will follow in due course. The decision to move ahead with the submission to NICE will have no impact on the company-sponsored early access programme offered through a number of NHS Trusts.